Eur Rev Med Pharmacol Sci 2019; 23 (4 Suppl): 51-54

DOI: 10.26355/eurrev_201911_19370

Tapentadol prolonged release for pain control in a frail obese patient: a case report

M.C. Iapichino

Ospedale Privato Accreditato Villa Pineta srl, Gaiato, Modena, Italy. iapichino.mariacinzia@villapineta.it


We present the case of a 59-year-old woman with third-grade obesity and severe comorbidities including osteoporosis, dyslipidemia, diabetes mellitus, hypertension, night eating following bariatric biliary-intestinal bypass surgery, severe fibromyalgia, poly-arthrosis, lumbar disc herniation in L5S1, sleep disorders and sleep apnea syndrome, and emotional disorders with anxiety and depression, who suffered from chronic pain unresponsive to a combination of multiple analgesics. After a period of metabolic and nutritional rehabilitation, analgesic treatment with tapentadol prolonged release (PR) was started and gradually increased to a daily dose of 300 mg with optimal pain control and a marked improvement in the quality of life and autonomy. Therapy suspension was followed by rebound pain with a worsening in functional capacity, and thus, the patient requested a new rehabilitation treatment, with new benefits.
Analgesia is of paramount importance in fragile patients who are undergoing a rehabilitation period, in order to improve compliance with the rehabilitation protocols and increase the success of behavioral therapy. Tapentadol PR can be an effective analgesic therapy for pain control in several settings. Its peculiar tolerability profile improves the acceptability of tapentadol, even in patients with multiple previous analgesic treatments.

Free PDF Download

To cite this article

M.C. Iapichino
Tapentadol prolonged release for pain control in a frail obese patient: a case report

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 4 Suppl
Pages: 51-54
DOI: 10.26355/eurrev_201911_19370